

**Agreement between quantitative and qualitative sensory testing of changes in orofacial somatosensory sensitivity.**

Journal:	<i>Journal of Oral Rehabilitation</i>
Manuscript ID	JOR-16-0266.R1
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Agbaje, Jimoh; Katholieke Universiteit Leuven, OMFS-IMPACT Research Group, Department of Imaging and Pathology, De Laat, Antoon; Catholic University of Leuven, Oral and Maxillofacial Surgery, School of Dentistry, Oral Pathology and Maxillo-Facial Surgery constantinus, Politis; KULeuven, Oral and maxillofacial surgery Svensson, Peter; Aarhus University, section of Orofacial Pain and Jaw Function Baad-Hansen, Lene; Aarhus University, section of Orofacial Pain and Jaw Function
Patient:	adult, adolescent
Condition:	neurosensory functioning
Co-morbidity:	Not applicable
Content method:	research, pain management
Study method:	clinical research

1  
2  
3 **Agreement between quantitative and qualitative sensory testing of changes in orofacial**  
4 **somatosensory sensitivity.**  
5  
6  
7

8  
9 Jimoh Agbaje<sup>1\*</sup>, Antoon De Laat<sup>2</sup>, Constantinus Politis<sup>1,3</sup>, Peter Svensson<sup>4,5</sup>, Lene Baad-Hansen<sup>4</sup>  
10  
11

12  
13  
14 <sup>1</sup>OMFS-IMPACT Research Group, Department of Imaging and Pathology, KU Leuven, Leuven,  
15  
16 Belgium  
17

18 <sup>2</sup>Department of Oral Health Sciences, KU Leuven, Leuven, Belgium  
19

20 <sup>3</sup>Oral and Maxillofacial Surgery, Leuven University Hospitals, Belgium  
21

22 <sup>4</sup>Section of Orofacial Pain and Jaw Function, Department of Dentistry, Aarhus University, Aarhus,  
23  
24 Denmark and Scandinavian Center for Orofacial Neurosciences (SCON)  
25

26 <sup>5</sup>Department of Dental Medicine, Karolinska Institutet, Huddinge, Sweden  
27

28 \* Corresponding author:  
29

30 Jimoh Agbaje  
31

32 OMFS-IMPACT Research Group, Department of Imaging and Pathology, Faculty of Medicine,  
33

34 Catholic University Leuven, Kapucijnenvoer 33, 3000 Belgium  
35

36 Business telephone number: +32 16 3 41963  
37

38 Fax: +32 16 3 32437  
39

40 Email: [joagbaje@gmail.com](mailto:joagbaje@gmail.com)  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

Qualitative somatosensory testing (QualST) is a simple chairside test. It can be used to roughly assess the presence or absence of altered somatosensory function. To use QualST clinically, it is important to assess its agreement with quantitative sensory testing (QST). The aims of this study were to assess the agreement between QST and QualST when testing the modulation of facial sensitivity by capsaicin in healthy participants and to explore the agreement between QST and QualST in assessing the intraoral sensory function in clinical atypical odontalgia (AO) patients. Eighteen healthy pain-free adults and data from 27 AO patients were included in the study.

Thirteen QST and three QualST parameters were evaluated at each site. Z-scores were computed for healthy participants and LossGain scores were created. The agreement observed between QST and QualST in participants with no alterations in facial sensation (placebo) was good, i.e. ranging from 89% to 94%. A poorer agreement was seen after capsaicin application in all test modalities with agreement ranging from 50% to 72%. The commonest misclassification observed was participants classified as normal according to QST, but hyper- or hyposensitive according to QualST after capsaicin application, especially for cold and pinprick. A similar trend was observed in AO patients where patients classified as normal using QST were misclassified as hypersensitive and in few patients as hyposensitive by QualST. In conclusion, the study showed that QualST may be used as a screening tool in the clinical setting, especially to show that subjects have normal sensory function.

## Key words

capsaicin; placebo; somatosensory profiling; quantitative sensory testing, qualitative sensory testing; atypical odontalgia

## Background

Nerve damage and altered sensation are common complications of orofacial trauma and some oral and maxillofacial treatments<sup>1-3</sup>. The resulting effect can range from mild complications such as transient hypoesthesia to life changing effects such as neuropathic pain<sup>4-7</sup>. Clinical symptoms of nerve damage such as altered sensations, e.g. somatosensory impairment, allodynia, persistent pain, pain and discomfort in the orofacial region, usually interfere negatively with daily activities<sup>8</sup>. Persistent uncontrollable postoperative pain and neuropathic pain are disabling iatrogenic conditions with severe medical, economic and psychological implications<sup>9-11</sup>. Early detection of nerve damage may aid treatment planning of nerve repair and lead to a reduction of the sensory impairment<sup>6,12-16</sup>.

A standardized battery of quantitative sensory testing (**QST**) was developed in 2006 by the German Research Network on Neuropathic Pain (Deutscher Forschungsverbund Neuropathischer Schmerz (DFNS)) to study somatosensory function<sup>17</sup>. This protocol has been proven to be sufficiently reliable for evaluation of gain or loss of somatosensory function at several body sites including the orofacial region<sup>18-21</sup>. The somatosensory profiles obtained from **QST** may be used to explore mechanisms behind different pain conditions but with regards to neuropathic pain, somatosensory profiles may vary quite a lot even within the same condition<sup>20,22</sup>.

Though **QST** is sufficiently reliable, its application in the clinical setting is limited as a result of a need for highly trained personnel required to operate the required equipment as well as the amount of time needed to complete the full battery of tests<sup>23</sup>. Therefore, a simpler and more qualitative clinical method to assess somatosensory testing has been advocated by some authors<sup>23-26</sup>. Qualitative somatosensory testing (QualST) is an example of such a simple chairside test<sup>23,26</sup>. It can be used to roughly assess the presence or not of altered somatosensory function. It is simple to apply and no extensive training and expensive equipment are needed. The test takes less than 5 min to perform but it provides information about crude hyposensitivity or hypersensitivity to touch, cold and pinprick stimuli. Though other stimulus modalities exist<sup>27</sup> these modalities cover the function of both A $\beta$ -, A $\delta$  and C-fibers<sup>23</sup>. QualST has been tested intraorally with promising results<sup>23</sup>. As a screening tool, it can be used as the first diagnostic method and patients that show altered sensation can then be referred to undertake a full battery of **QST** to better document their condition. This may possibly save

1  
2  
3 time and costs and allow screening before and after surgery, especially in procedures with possible  
4 risk of nerve damage. However, in order to be able to recommend this test in the future, it is important  
5 to assess its agreement with QST.  
6  
7

8  
9 The aim of this study was therefore to assess the level of agreement between quantitative and  
10 qualitative sensory testing of experimental modulation of facial sensitivity with capsaicin in a  
11 randomized placebo-controlled cross-over manner in healthy individuals. We hypothesized that the  
12 agreement between QualST and QST was sufficient for QualST to be used as a screening tool in the  
13 clinical setting. Another aim was to further explore the agreement between QST and QualST in  
14 assessing the intraoral somatosensory function in clinical atypical odontalgia (AO) patients.  
15  
16  
17  
18  
19  
20  
21  
22

### 23 **Materials and Methods**

24 Eighteen healthy pain-free adults (> 18 years) were included in the study (10 women, 8 men, mean  
25 age ( $\pm$  SD)  $30.9 \pm 5.8$  years). The participants were recruited through advertisements at Aarhus  
26 University and the local community. The inclusion criteria were: > 18 years old. Exclusion criteria  
27 were: known systemic problems, current or previous radiotherapy or chemotherapy, intake of any type  
28 of analgesics in the last 24 hours prior to the study, presence of any orofacial pain conditions,  
29 presence of self-reported psychiatric or personality disorders. The sample size was based on  
30 knowledge from earlier studies<sup>17-19,21,22</sup> on the variance of QST measures performed in the orofacial  
31 region taking into account the paired study design.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 The study was performed in accordance with the Helsinki Declaration II. The study protocol  
43 was approved by the ethics committee of Central Denmark Region. Full explanation of all procedures  
44 was given to all participants, after which they signed a written informed consent.  
45  
46

47 Data from an earlier study using QST and QualST in the chronic intraoral pain condition AO  
48 patients were further explored<sup>23</sup>. The 27 AO patients consist of 23 women and 4 men with a mean age  
49 ( $\pm$  SD) of  $63 \pm 14$  years).  
50  
51  
52  
53  
54

### 55 *Study Design*

56  
57  
58  
59  
60

1  
2  
3 The study was designed as a randomized, placebo-controlled cross-over study. All healthy  
4 participants were evaluated in two sessions by the same male examiner (one session per tested  
5 condition). The tested conditions were: Topical capsaicin and placebo. The tested areas were the right  
6 or left infraorbital region of the participants. The condition as well as test side were randomly chosen  
7 for each participant. Participants were blinded to the condition being tested. Each test was separated  
8 by at least three days. Qualitative sensory testing (QualST) as well as Quantitative sensory testing  
9 (QST) were performed on the selected side before and after application in each session.  
10  
11  
12  
13  
14  
15  
16  
17  
18

### 19 *Topical application*

20 The concentration of capsaicin and the time-period of application were chosen based on the results of  
21 earlier studies<sup>25,28</sup>. The topical application of capsaicin was used to provoke mild to moderate pain  
22 that lasted throughout the test period. In this study, 0.1% capsaicin cream (Capzasin-HP, Chatterm,  
23 Inc, USA) was used to provoke mild to moderate pain and Mepore Pro Plaster (Mölnlycke Healthcare  
24 AB, Göteborg, Sweden) was used as the placebo. A thin layer of capsaicin applied on a 4x4-cm  
25 Mepore pro plaster, or a 4x4-cm Mepore pro plaster (placebo), was applied on the infraorbital region  
26 of participants. Participants were asked to score the perceived pain intensity every minute during the 5  
27 min of application using a 0-10 Numerical rating scale (NRS) (0 = 'no pain', 10 = 'most pain  
28 imaginable').  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

### 41 *Measurement process*

42  
43 *Extraoral qualitative sensory testing* The applied QualST technique has been previously described in  
44 detail<sup>23</sup>. In short, the sensitivity to touch, cold, and pinprick stimuli were evaluated on the test site  
45 compared with the contralateral site. The stimuli were applied to the contralateral site first, followed  
46 by the test site (application side), and always in the same order: (1) touch, (2) cold, and (3) pinprick<sup>23</sup>.  
47 The touch stimulus was applied with a Q-tip in a single stroke over 1 to 2 cm of skin<sup>23</sup>. The cold  
48 stimulus was applied with a stainless steel dental spatula (kept cool in ice water, approximately 0°C)  
49 for 1 to 2 s<sup>23</sup>. The pinprick stimulus was applied with a dental examination probe with moderate force  
50 on the skin for 1 to 2 s<sup>23</sup>. Participants were asked to report hypersensitivity, hyposensitivity, or  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 normosensitivity to touch, cold, and painful stimuli on the test site compared with the control  
4  
5 contralateral site<sup>22,23</sup>.

6  
7  
8  
9 *Extraoral quantitative sensory testing* A standardized quantitative somatosensory examination,  
10 according to the protocol of the DFNS for extraoral application, was used<sup>17,29</sup>. Briefly, the  
11 quantitative somatosensory examination was comprised of 13 test parameters and investigated the  
12 following sensory functions in the following sequence: The tests for thermal sensation were  
13 performed using a PATHWAY (MEDOC, Ramat Yishai, Israel) thermal sensory testing device. Cold  
14 detection threshold (CDT) and warmth detection threshold (WDT) were measured first. The number  
15 of paradoxical heat sensations (PHS) was determined during the thermal sensory limen (TSL)  
16 procedure, followed by cold pain threshold (CPT) and heat pain threshold (HPT)<sup>17</sup>. The baseline  
17 temperature was 32°C, and all thresholds were obtained with ramped stimuli (1°C/ s) that were  
18 terminated when the participant pressed a button<sup>17</sup>. Cut-off temperatures were 0 and 50°C, and the  
19 contact area of the extra-oral thermode was 9.0 cm<sup>2</sup><sup>17</sup>. During the experiment, the participants were  
20 discouraged from looking at the computer screen.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 Mechanical detection thresholds (MDTs) were measured using a standardized set of modified  
34 von Frey filaments (OptiHair; MARSTOCK Nervtest, Marburg, Germany), which exert forces  
35 between 0.25 and 512 mN<sup>17</sup>. The contact area of the von Frey hairs were rounded tips, 0.5 mm in  
36 diameter, to avoid sharp edges that would facilitate nociceptor activation<sup>17,21</sup>. The filament was  
37 applied perpendicular to the test site, and the pressure was slowly increased until the filament began to  
38 bend<sup>18</sup>. The time needed to bend was standardized to about 1–2 s, and the stimulus was maintained  
39 for 1–2 s<sup>17,21</sup>. The final threshold was the geometric mean of five series of ascending and descending  
40 stimulus intensities, where the participant was asked to indicate each time a stimulus was perceived  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 Mechanical pain thresholds (MPT) were measured using custom-made weighted pinprick  
54 stimulators (Aarhus University, Aarhus, Denmark) with fixed-stimulus intensities between 8 and 512  
55 mN<sup>17,22</sup>. The final threshold of painful pricking or stinging sensation was the geometric mean of five  
56 series of ascending and descending stimulus intensities<sup>17,19</sup>. Mechanical pain sensitivity (MPS) was  
57  
58  
59  
60

1  
2  
3 tested using the same weighted pinprick stimuli as for MPT<sup>17</sup>. In addition, dynamic mechanical  
4 allodynia (ALL) were tested using three light tactile stimulators: a cotton wisp (~3 mN), a cotton-  
5 wool tip (~100 mN), and a Somedic brush (~200–400 mN)<sup>17,22</sup>. Each of the seven intensities of  
6 pinprick and of the three intensities of light stroking was applied five times in a balanced sequence  
7 and the subjects were asked to give a pain rating for each stimulus on a 0–100 numerical rating scale  
8 (from 0 = 'no pain' to 100 = 'most pain imaginable'). The MPS was calculated as the geometric mean  
9 of all pain ratings for pinprick stimuli, and allodynia was calculated as the geometric mean of all pain  
10 ratings for light touch stimuli<sup>17,21</sup>.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20 The wind-up ratio (WUR) was evaluated using a single pinprick stimulus and 10 pinprick  
21 stimuli with the same force, repeated at a rate of 1 Hz and kept constant using a metronome (MA-30;  
22 Korg, New York, USA)<sup>17</sup>. Three single pinprick stimuli were alternated with three series of 10  
23 repeated stimuli. The mean pain rating of the series was then divided by the mean pain rating of single  
24 stimuli (train/single pinprick) to calculate the WUR<sup>17,21</sup>.

25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
The vibration detection threshold (VDT) test was performed using a Rydel-Seiffer tuning fork  
(64 Hz, 8/8 scale)<sup>17</sup> that was set in motion and placed in contact with the zygomatic arch of maxilla.  
The VDT was determined as a disappearance threshold on the 8/8 scale with three stimulus repetitions  
<sup>17,21</sup>.

The pressure pain threshold (PPT) was measured using a digital pressure algometer  
(SOMEDIC Algometer, SOMEDIC Sales, Hörby, Sweden) with a rubber-coated tip of 1 cm in  
diameter. During the test, pressure was increased at a rate of 50 kPa /s)<sup>17,21</sup>. At the first painful  
sensation the subjects pressed a button to interrupt stimulation. The PPT was determined as the mean  
of three recordings<sup>17,21</sup>.

#### *Statistical analyses*

All absolute **QST** scores are presented as means ± standard deviation (SD). All **QST** data, except for  
PHS, CPT, HPT, and VDT, were logarithmically transformed before statistical analysis<sup>17</sup>. The mean  
and SD of all **QST** parameters of all healthy subjects at baseline was calculated and served as the  
reference for the Z-transformed **QST** parameters obtained after application. The **QST** parameters of



1  
2  
3 each subject were transformed into a Z-score using the following equation:  $Z\text{-score} = (\text{Value}_{\text{subject}} -$   
4  $\text{Mean}_{\text{baseline}}) / \text{SD}_{\text{baseline}}$  (negative Z-score: loss of sensory function, positive Z-score: gain in sensory  
5 function) <sup>17,22</sup>. Z-scores of  $>1.96$  and  $<-1.96$  indicate somatosensory sensitivity outside the 95% CI of  
6 the baseline sensitivity of the healthy subjects <sup>17</sup>. P values less than 0.05 were considered statistically  
7 significant.  
8  
9

10  
11  
12 The Loss-Gain score was used to combine a score of somatosensory loss of function (L0, L1,  
13 L2, or L3) with a score of somatosensory gain of function (G0, G1, G2, or G3) <sup>30,31</sup>. The number after  
14 the 'L' or 'G' was used to indicate, whether the somatosensory abnormality was related to the thermal  
15 modalities alone (1), mechanical modalities alone (2) or mixed (3) (thermal and mechanical) <sup>22</sup>. L0  
16 and G0 were used to indicate no loss or gain of somatosensory function, respectively. L1 indicated  
17 isolated loss of small fiber function (if thermal detection thresholds (CDT or WDT) is abnormal); L2  
18 indicated isolated loss of large fiber function (if mechanical detection thresholds (MDT or VDT) is  
19 abnormal), and L3 indicated mixed loss of function (if loss of both small and large fiber function) <sup>20,22</sup>.  
20 For somatosensory gain, G1 indicated thermal hyperalgesia, if gain of function in cold or heat pain  
21 thresholds (CPT or HPT) was found. G2 indicated mechanical hyperalgesia, if gain of function was  
22 detected for mechanical pain threshold (MPT), mechanical pain sensitivity (MPS), pressure pain  
23 threshold (PPT) or if the dynamic mechanical allodynia (DMA) score exceeded 0. G3 indicating  
24 mixed gain of somatosensory function was recorded in individuals with gain of both thermal and  
25 mechanical somatosensory function <sup>20,22</sup>.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 To assess the agreement between QST and QualST, the Z-scores were categorized as normal,  
42 when Z-scores were between 1.96 and -1.96, hypersensitive, when the Z-scores were  $>1.96$  or  
43 hyposensitive, when the Z-scores were  $<-1.96$ . Using the Loss-Gain coding <sup>30,32</sup>, the absolute  
44 agreement between QualST (3 modalities) and QST (LossGain codes) was calculated as the  
45 proportion of the group where hyposensitivity to touch in QualST was in agreement with a L2 or L3  
46 score (both including tactile loss) <sup>22</sup>. Similar proportions were computed for the proportions of the  
47 groups showing agreement between hypersensitivity to touch (QualST) and G2 or G3 score;  
48 hyposensitivity to cold (QualST) and L1 or L3 score; hypersensitivity to cold (QualST) and G1 or G3  
49 score; hypersensitivity to pinprick (QualST) and G2 or G3 score <sup>22</sup>.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 In addition, the sensitivity and specificity of QualST to detect hyper- and hyposensitivity was  
4  
5 evaluated using QST as a benchmark. Kappa statistic was not performed in the present study due to its  
6  
7 shortcomings such as dependence on marginal sum as well as prevalence of examining condition<sup>33,34</sup>.  
8  
9 These shortcomings make kappa to have a wide confidence interval that may include anything from  
10  
11 good to poor agreement<sup>34</sup>. Furthermore, a supplementary explorative analysis of data from a previous  
12  
13 study was done in order to further investigate the agreement between QST and QualST in assessing  
14  
15 the intraoral sensory function in clinical atypical odontalgia (AO) patients<sup>22</sup>.  
16

17  
18 NRS pain scores for capsaicin were compared between baseline up till 5 minute post  
19  
20 application period with a one-way ANOVA test.

21  
22 The QST parameters were analyzed with two-way repeated measurements (RM) analyses of  
23  
24 variance (ANOVAs) with condition (capsaicin and placebo) and time (before and after application) as  
25  
26 factors. Tukey honestly significant difference (HSD) tests with correction for multiple comparisons  
27  
28 were used for post hoc analysis when appropriate. All tests were carried out using the STATISTICA,  
29  
30 v 12 (StatSoft Inc., USA) Statistical Package.  
31

## 32 33 **Results**

### 34 35 QST/QualST findings

36  
37 The healthy participants' responses to test conditions as recorded by QST and QualST are presented  
38  
39 in Table 1. In two-third of healthy participants, QST recorded normal sensation to touch and cold  
40  
41 after the application of capsaicin, while QualST recorded only one-third of the participants as having  
42  
43 normal sensation after capsaicin application.  
44  
45

### 46 47 *Agreement between QST and QualST (healthy participants)*

#### 48 49 *Percentage agreement*

50  
51 The absolute percentage agreement between corresponding measures from QST and the three  
52  
53 modalities of QualST is presented in Table 2. The percentage agreement of touch hyposensitivity or  
54  
55 hypersensitivity for QualST and mechanical loss (L2 or L3) or gain (G2 or G3) from QST was 61%  
56  
57  
58  
59  
60

1  
2  
3 (capsaicin session) and 89% (Placebo), while absolute agreement between cold hyposensitivity or  
4 hypersensitivity from QualST and QST (L1 or L2) or (G1 or G3) was 50% (Capsaicin) and 89%  
5  
6  
7 (Placebo). The percentage absolute agreement of hypersensitivity to pinprick for QualST and  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

(capsaicin session) and 89% (Placebo), while absolute agreement between cold hyposensitivity or hypersensitivity from QualST and QST (L1 or L2) or (G1 or G3) was 50% (Capsaicin) and 89% (Placebo). The percentage absolute agreement of hypersensitivity to pinprick for QualST and mechanical gain (G2 or G3) from QST was 72% (Capsaicin) and 94% (placebo). Very little absolute disagreement between QualST and QST was recorded in the capsaicin session in touch and cold modalities (one subject each). In both cases QST indicated hypersensitivity while QualST indicated hyposensitivity.

#### *Changes in classification from QST to QualST (healthy participants)*

Using QST as a benchmark, we compared the corresponding score of QualST for the condition and test modality used to assess facial sensitivity. Figure 1 shows the classification distribution between QST and QualST in healthy participants. There was better agreement after placebo application than after capsaicin for all test modalities.

#### *Sensitivity and specificity (healthy participants)*

The sensitivity and specificity of corresponding measures from QST and the three modalities of QualST in healthy participants are presented in Table 3. The sensitivity was calculated as the probability of a modality being classified as hyper- or hyposensitive with QualST when the subject was classified as hyper- or hyposensitive with QST. The sensitivity of QualST modalities to detect hyposensitivity ranged from 0.6 to 1.0 with cold modalities presenting the lowest sensitivity after application of capsaicin. While the specificity to detect hyposensitivity ranged from 0.5 to 1.0 with the lowest specificity value seen in touch modality after application of capsaicin Table 3.

Since no subject was classified as hyper- or hyposensitive with QST or QualST, no estimate (“-“) for the sensitivity was obtained (Table 3). No subjects were classified as hypersensitive in conditions such as capsaicin and placebo. All subjects classified as hypersensitive to pinprick by QualST was also classified as hypersensitive by QST giving a sensitivity of 1.0. The specificity to detect hypersensitivity ranged from 0.7 to 1.0 (Table 3).

1  
2  
3 | *Agreement between QualST and QST in AO patients*

4 | *Changes in classification from QST to QualST (AO patients)* The percentage agreement between  
5 | corresponding measures of QST and QualST in AO patients has been published before <sup>23</sup>. The  
6 | classification distribution between QST and QualST in AO patients when QST is used as the  
7 | benchmark is shown in Fig. 2.  
8 |  
9 |  
10 |  
11 |

12 |  
13 |  
14 |  
15 | *Pain evoked by topical application*

16 | All **healthy participants** scored application of capsaicin as painful. The mean peak pain induced by  
17 | capsaicin was  $8.0 \pm 2.0$ , after 5 min. The mean NRS score after capsaicin application increased with  
18 | time (ANOVA:  $F = 116.35$ ,  $p = 0.001$ ) (Fig. 3). No participant scored placebo as painful at any time  
19 | point (Fig. 3).  
20 |  
21 |  
22 |  
23 |

24 |  
25 |  
26 |  
27 | *QST findings (healthy participants)*

28 | There were no significant main effects of session (ANOVA:  $F = 1.96$ ,  $p = 0.179$ ) or time (ANOVA:  $F$   
29 |  $= 7.39$ ,  $p = 0.014$ ) on CDT scores but there was a statistically significant interaction between session  
30 | and time (ANOVA:  $F = 13.24$ ,  $p = 0.002$ ). The post hoc analysis showed that application of capsaicin  
31 | induced a significant decrease in CDT (sensory loss) compared with baseline (Tukey:  $p = 0.001$ ) and  
32 | placebo (Tukey:  $p = 0.019$ ) (Fig. 4).  
33 |  
34 |

35 | There were main effects of session (ANOVA:  $F = 11.56$ ,  $p = 0.003$ ) and time (ANOVA:  $F =$   
36 |  $11.91$ ,  $p < 0.001$ ), but without significant interactions, for the WDT. The WDT scores in the capsaicin  
37 | session were significantly lower (sensory gain) compared with the placebo session (Tukey:  $p <$   
38 |  $0.003$ ). The post hoc analysis of the time effect indicated higher WDTs after applications compared  
39 | with before applications (Tukey:  $p < 0.001$ ) (Fig. 4).  
40 |

41 | There was no significant main effect of session (ANOVA:  $F = 0.74$ ,  $p = 0.401$ ) on TSL  
42 | values. However, there was a significant main effect of time (ANOVA:  $F = 46.09$ ,  $p < 0.001$ ). The  
43 | post hoc analysis showed significantly higher TSL values (decreased sensitivity) after application  
44 | compared to the pre-application values ( $P < 0.001$ ) (Fig. 4).  
45 |  
46 |  
47 |  
48 |  
49 |

1  
2  
3 There was a main effect of session (ANOVA:  $F = 7.13$ ,  $p = 0.016$ ) and time ( $F = 5.98$ ,  $p =$   
4  $0.026$ ) on CPT. Also, there was a statistically significant interaction between session and time  
5 (ANOVA:  $F = 1129$ ,  $p < 0.001$ ). The post hoc analysis of the session effect showed that CPT values  
6 during the capsaicin session were significantly lower (sensory loss) than in the placebo session  
7 (Tukey:  $p < 0.016$ ). The post hoc analysis of the interaction between session and time indicated that  
8 post application values of CPT during the capsaicin session were lower than at baseline (Tukey:  $p <$   
9  $0.001$ ) and in comparison with post application values in the placebo sessions (Tukey:  $p < 0.001$ )  
10 (Fig. 4).  
11  
12

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
There were main effects of session (ANOVA:  $F = 17.01$ ,  $p < 0.001$ ) and time (ANOVA:  $F =$   
20.86,  $p < 0.001$ ) on HPT. Also, there was a statistically significant interaction between session and  
time (ANOVA:  $F = 19.90$ ,  $p < 0.001$ ). The post hoc analysis of the main session effect indicated that  
the HPT values during the capsaicin session were significantly lower (sensory gain) compared with  
the placebo session (Tukey:  $p < 0.001$ ). The post hoc analysis of the main effect of time indicated  
slight decreases in HPT values post application compared with baseline (Tukey:  $p < 0.001$ ). The post  
hoc analysis of the interaction between session and time indicated a significant decrease in HPT after  
capsaicin application compared with baseline (Tukey:  $p < 0.001$ ) and compared with after application  
of placebo (Tukey:  $p < 0.0001$ ) (Fig. 4).

There was a tendency towards a significant main effect of session (ANOVA:  $F = 4.38$ ,  $p =$   
 $0.052$ ) on MDT values. However, there was a significant main effect of time (ANOVA:  $F = 17.64$ ,  $p$   
 $< 0.001$ ). The post hoc analysis of the time effect indicated higher MDTs after applications compared  
with baseline (Tukey:  $p < 0.001$ ) (Fig. 5).

There was no significant main effects of session (ANOVA:  $F = 0.88$ ,  $p = 0.362$ ) or time  
(ANOVA:  $F = 0.77$ ,  $p < 0.392$ ) on MPT. Also, there was no statistically significant interaction  
between session and time (ANOVA:  $F = 1.00$ ,  $p = 0.330$ ) (Fig. 5).

There was a significant main effect of session (ANOVA:  $F = 4.72$ ,  $p = 0.044$ ) but no main  
effect of time (ANOVA:  $F = 1.22$ ,  $p < 0.284$ ) on MPS values. The post hoc analysis of the session  
effect indicated higher MPS values (sensory gain) in the capsaicin session compared with placebo  
(Tukey:  $p = 0.044$ ) (Fig. 5).

1  
2  
3 There was no significant main effects of session (ANOVA:  $F = 0.55$ ,  $p = 0.468$ ) but a  
4 tendency towards a significant main effect of time (ANOVA:  $F = 4.16$ ,  $p = 0.057$ ) on WUR. Also,  
5 there was no statistically significant interaction between session and time (ANOVA:  $F = 0.67$ ,  $p =$   
6  
7  
8  
9  
10 0.423) (Fig. 5).

11 There was no significant main effects of session (ANOVA:  $F = 2.51$ ,  $p = 0.131$ ) or time  
12 (ANOVA:  $F = 1.27$ ,  $p = 0.275$ ) on VDT scores but there was a statistically significant interaction  
13 between session and time (ANOVA:  $F = 9.58$ ,  $p = 0.006$ ). The post hoc analysis of the interaction  
14 between session and time indicated significantly lower values of VDT after application of capsaicin  
15 compared with baseline (Tukey:  $p < 0.027$ ).  
16  
17  
18  
19  
20

21 There was no significant main effect of session (ANOVA:  $F = 0.30$ ,  $p = 0.587$ ) or time  
22 (ANOVA:  $F = 3.83$ ,  $p = 0.067$ ) on PPT scores but there was a statistically significant interaction  
23 between session and time (ANOVA:  $F = 7.04$ ,  $p = 0.017$ ). The post hoc analysis of the interaction  
24 indicated that application of capsaicin induced a significant increase in PPT (sensory loss) compared  
25 with baseline (Tukey:  $p = 0.033$ ) (Fig. 5).  
26  
27  
28  
29  
30  
31  
32

### 33 Discussion

34  
35  
36 This study assessed the level of agreement between quantitative and qualitative sensory testing  
37 assessing the modulation of facial sensitivity by capsaicin and placebo. The test conditions simulated  
38 some observed orofacial somatosensory alterations seen after for example after oral surgery. The  
39 study also reported on the degree of agreement between quantitative and qualitative sensory testing in  
40 patients with a chronic primary intraoral pain condition, i.e., atypical odontalgia.  
41  
42  
43  
44  
45  
46

#### 47 Agreement between *QST* and *QualST*

48  
49 A good agreement was observed between quantitative and qualitative sensory testing in healthy  
50 participants with no alterations in facial sensation (placebo) with agreement ranging from 89% to 94%  
51 of the tested participants. The least agreement was seen after capsaicin application in all test  
52 modalities with agreement ranging from 50% to 72%. For most conditions the agreement between  
53  
54  
55  
56  
57  
58  
59  
60 *QST* and *QualST* was high for the sensitivity to pinprick (72 - 94%) while the least agreement was

1  
2  
3 observed with sensitivity to cold (Table 2). This finding is in agreement with a previous study where  
4  
5 good agreement was found between QST and QualST regarding thermal and mechanical modalities in  
6  
7 healthy subjects <sup>22</sup>.  
8

9  
10 QualST seemed to detect more somatosensory anomaly (hyper/hypo) in all  
11  
12 sessions/conditions than QST both in healthy participant and AO patients (Tables 1 <sup>23</sup>). This could  
13  
14 either mean that QualST tended to induce more false positive responses, or it could mean that the  
15  
16 sensitivity of QST is low due to the wide range of normal responses. Since no gold standard is  
17  
18 available, this issue is difficult to settle. However, future studies in clinical patient populations with a  
19  
20 definite diagnosis of neuropathic pain could be used to observe the degree of agreement between QST  
21  
22 and QualST in the patients with an electrophysiological or imaging test documenting a nerve lesion.  
23

#### 24 *Changes in classification between QST and QualST*

25  
26  
27 Fig. 1 shows the classification distribution between QST and QualST in healthy participants. The best  
28  
29 agreement was seen in placebo, which indicates that QualST was able to detect normal sensitivity as  
30  
31 normal in about 90% of cases. The high level of specificity shown by QualST reflects the probability  
32  
33 that the QualST will be negative among those who, in fact, do not have somatosensory anomaly. The  
34  
35 commonest misclassification observed was the classification of normal according to QST as  
36  
37 hyposensitivity by QualST. After capsaicin application, participants classified as normal using QST  
38  
39 were misclassified as hyper- or hyposensitive using QualST especially for cold and pinprick. A  
40  
41 similar trend was observed in the further exploration of earlier reported data on AO patients, where  
42  
43 patients classified as normal using QST were misclassified as hypersensitive and in few patients as  
44  
45 hyposensitive using QualST (Figure 2). Some patients scored by QST as hypersensitive were scored  
46  
47 by QualST as hyposensitive especially in touch and pinprick. This misclassification may result from  
48  
49 differences in the psychophysical method and responses obtained from the patients between the two  
50  
51 systems (QST and QualST). In QualST, patients were asked to evaluate their sensitivity to the  
52  
53 different modalities by comparing one side to the other <sup>23</sup>, whereas with QST somatosensory  
54  
55 sensitivity was evaluated based on the means and SDs of the reference <sup>17,18</sup>.  
56  
57  
58  
59  
60

1  
2  
3 Although QualST was able to categorize most healthy participants without experimental  
4 modulation of facial sensitivity as having normal sensory function, its inconsistency in assessing  
5 facial sensitivity after experimental modulation in healthy participants or in clinical AO patients <sup>23</sup>  
6  
7 should be taken into consideration when used for patient screening.  
8  
9

10  
11 In all 18 healthy subjects, topical application of capsaicin to the infraorbital region caused a  
12 severe level of pain. The pain observed in this study was higher than what was reported in a previous  
13 study, where capsaicin was applied to the gingiva <sup>19</sup>. The observed high level of pain in the  
14 infraorbital region in comparison with gingiva may be due to differences in the C-fiber densities  
15 between the tissues <sup>25,35</sup>  
16  
17

18  
19 In the present study, the application of capsaicin increased CDT and CPT (decreased  
20 sensitivity) and reduced HPT (increased sensitivity), which is in accordance with previous studies  
21 <sup>19,36</sup>. These thermal threshold differences were statistically significant in the direct comparison of data  
22 obtained before and after application. In terms of the mechanical stimuli, topical application of  
23 capsaicin induced reduced sensitivity to painful mechanical stimuli (the PPT increased), which is in  
24 accordance with what was obtained with intraoral application, where topical application of capsaicin  
25 to the attached gingiva induced decreased mechanical sensitivity <sup>19</sup>. However, in contrast, other  
26 studies on the skin have shown increase in mechanical sensitivity after topical application or  
27 intradermal injection of capsaicin in human subjects <sup>37-39</sup> It could be considered a limitation of the  
28 present study that capsaicin application may cause the self-unblinding due to its burning sensation.  
29 However, but we do not believe that this influences the agreement between QST and QualST  
30 measurements.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 Some of the observed changes in somatosensory sensitivity after topical applications were not  
49 specific to the application of capsaicin but also occurred after placebo, suggesting that the altered  
50 sensitivity to some test stimuli (WDT, TSL and MDT) after application could be speculated to be  
51 sensitizations or adaptations to the stimuli rather than changes induced by application <sup>19,40</sup>. This fact  
52 stresses the need for a control condition in studies such as this.  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 The full **QST** somatosensory Z-score profile after application of capsaicin and placebo were  
4 also reported in the present study. The mean and SD of the **QST** baseline values (before application)  
5 were used as the reference values to compute the Z-scores as done in previous studies<sup>19,32,41</sup>. In the  
6 present study, inspection of the individual Z-scores demonstrated decreased sensitivity towards non-  
7 painful cold, warmth and tactile stimuli and increased sensitivity to pinprick and vibratory stimuli as  
8 well as increased wind-up after application of capsaicin (Fig. 6).  
9  
10  
11  
12  
13  
14

15  
16 However, the other findings observed from the direct comparison of values obtained before  
17 and after application of the test substances (Fig. 4 & 5) could not be identified in the Z- scores and the  
18 somatosensory profiles (Fig. 6). This may be due to the natural variation in values that were used to  
19 create the Z-scores. Thus, the Z-score transformation may only be able to illustrate the most robust  
20 findings because minor, but still significant, group differences detected in the statistical comparison of  
21 absolute values were not represented as mean Z-scores outside 95% CI of the baseline values<sup>36</sup>.  
22  
23  
24  
25  
26  
27

28  
29 In summary, we observed and confirmed that a standardized **QST** battery and Z-score-based  
30 somatosensory profiling indicated that topical application of capsaicin may be considered as an  
31 effective surrogate model of extra-oral pain with concomitant somatosensory disturbances.  
32  
33  
34  
35  
36  
37

### 38 **Conclusion**

39  
40 In conclusion, the study showed a good level of agreement (89% to 94%) between quantitative and  
41 qualitative sensory testing in participants with no alterations in facial sensation (placebo). This result  
42 showed that QualST may be used as a screening tool in the clinical setting, especially to show that  
43 subjects have normal sensory function. However, in case of experimental modulation of facial  
44 somatosensory sensitivity as well as in patients with chronic orofacial pain (AO patients) agreement  
45 was less pronounced between quantitative and qualitative sensory testing. This has clinical  
46 implications for the interpretation of QualST as a screening tool in patients with somatosensory  
47 changes and this should be taken into consideration when it is used in the clinical settings.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Acknowledgment

The authors report no conflicts of interest related to this study. Agbaje Jimoh Olubanwo is a postdoctoral researcher of the Fund for Scientific Research (FWO-Vlaanderen).

## Figure Legends

Figure 1: Change in classification from quantitative sensory testing (QST) to qualitative sensory testing (QualST) in **healthy** participants. 0: normal; 1: hypersensitivity; 2: hyposensitivity.

Figure 2 : Change in classification from quantitative sensory testing (QST) to qualitative sensory testing (QualST) in AO patients. 0: normal; 1: hypersensitivity; 2: hyposensitivity.

Figure 3: **Healthy participants**-reported Numerical Rating Scale (NRS) pain scores  $\pm$  (SEM) after the topical application of capsaicin and placebo on the infra-orbital region. The results represent mean values (n = 18) obtained during the 5 min recording period.

Figure 4 & 5: Mean ( $\pm$ SD) of quantitative sensory testing (QST) parameters for tested condition before and after application **in healthy participants**.

Figure 6: Individual Z-score-based quantitative sensory testing (QST) profiles from the infraorbital region after the application of capsaicin and placebo **in healthy participants** and the averaged Z-scores (C) (n = 18). The grey area ( $-1.96 < z < 1.96$ ) is the normal range based on the healthy reference. CDT: cold detection threshold; WDT: warmth detection; TSL: thermal sensory limen; CPT: cold pain threshold; HPT: heat pain threshold; MDT: mechanical detection threshold; MPT:

1  
2  
3 mechanical pain threshold; MPS: mechanical pain sensitivity; WUR: wind-up ratio; VDT: vibration  
4  
5 detection threshold; PPT: pressure pain threshold.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

### 20 Reference List

- 21  
22  
23  
24 (1) Wijbenga JG, Verlinden CR, Jansma J, Becking AG, Stegenga B. Long-lasting  
25 neurosensory disturbance following advancement of the retrognathic mandible: distraction  
26 osteogenesis versus bilateral sagittal split osteotomy. *Int J Oral Maxillofac Surg*  
27 2009;38:719-725.  
28  
29  
30  
31  
32 (2) Yamauchi K, Takahashi T, Kaneuji T, Nogami S, Yamamoto N, Miyamoto I et al. Risk  
33 factors for neurosensory disturbance after bilateral sagittal split osteotomy based on  
34 position of mandibular canal and morphology of mandibular angle. *J Oral Maxillofac Surg*  
35 2012;70:401-406.  
36  
37  
38  
39  
40 (3) Yoshioka I, Tanaka T, Khanal A, Habu M, Kito S, Kodama M et al. Relationship between  
41 inferior alveolar nerve canal position at mandibular second molar in patients with  
42 prognathism and possible occurrence of neurosensory disturbance after sagittal split ramus  
43 osteotomy. *J Oral Maxillofac Surg* 2010;68:3022-3027.  
44  
45  
46  
47  
48 (4) Phillips C, Essick G. Inferior alveolar nerve injury following orthognathic surgery: a review  
49 of assessment issues. *J Oral Rehabil* 2011;38:547-554.  
50  
51  
52  
53 (5) Politis C, Sun Y, Lambrechts I, Agbaje JO. Self-reported hypoesthesia of the lower lip after  
54 sagittal split osteotomy. *Int J Oral Maxillofac Surg* 2013;42:823-829.  
55  
56  
57  
58  
59  
60

- 1  
2  
3 (6) Politis C, Lambrichts I, Agbaje JO. Neuropathic pain after orthognathic surgery. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2014;117:e102-e107.  
4  
5  
6  
7  
8 (7) Renton T. Prevention of iatrogenic inferior alveolar nerve injuries in relation to dental  
9 procedures. *Dent Update* 2010;37:350-6, 358.  
10  
11  
12 (8) D'Agostino A, Trevisiol L, Gugole F, Bondi V, Nocini PF. Complications of orthognathic  
13 surgery: the inferior alveolar nerve. *J Craniofac Surg* 2010;21:1189-1195.  
14  
15  
16  
17 (9) Al-Bishri A, Rosenquist J, Sunzel B. On neurosensory disturbance after sagittal split  
18 osteotomy. *J Oral Maxillofac Surg* 2004;62:1472-1476.  
19  
20  
21  
22 (10) Leira JJ, Gilhuus-Moe OT. Sensory impairment following sagittal split osteotomy for  
23 correction of mandibular retrognathism. *Int J Adult Orthodon Orthognath Surg* 1991;6:161-  
24 167.  
25  
26  
27  
28 (11) Smith JG, Elias LA, Yilmaz Z, Barker S, Shah K, Shah S et al. The psychosocial and  
29 affective burden of posttraumatic neuropathy following injuries to the trigeminal nerve. *J*  
30 *Orofac Pain* 2013;27:293-303.  
31  
32  
33  
34 (12) Donoff RB. Surgical management of inferior alveolar nerve injuries (Part I): The case for  
35 early repair. *J Oral Maxillofac Surg* 1995;53:1327-1329.  
36  
37  
38  
39 (13) Pogrel MA, Jergensen R, Burgon E, Hulme D. Long-term outcome of trigeminal nerve  
40 injuries related to dental treatment. *J Oral Maxillofac Surg* 2011;69:2284-2288.  
41  
42  
43  
44 (14) Renton T, Yilmaz Z. Profiling of patients presenting with posttraumatic neuropathy of the  
45 trigeminal nerve. *J Orofac Pain* 2011;25:333-344.  
46  
47  
48  
49 (15) Renton T, Yilmaz Z. Managing iatrogenic trigeminal nerve injury: a case series and review  
50 of the literature. *Int J Oral Maxillofac Surg* 2012;41:629-637.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 (16) Zuniga JR, Yates DM, Phillips CL. The presence of neuropathic pain predicts postoperative  
4 neuropathic pain following trigeminal nerve repair. *J Oral Maxillofac Surg* 2014;72:2422-  
5 2427.  
6  
7  
8  
9  
10 (17) Rolke R, Baron R, Maier C, Tolle TR, Treede RD, Beyer A et al. Quantitative sensory  
11 testing in the German Research Network on Neuropathic Pain (DFNS): standardized  
12 protocol and reference values. *Pain* 2006;123:231-243.  
13  
14  
15  
16 (18) Baad-Hansen L, Pigg M, Yang G, List T, Svensson P, Drangsholt M. Reliability of intra-  
17 oral quantitative sensory testing (QST) in patients with atypical odontalgia and healthy  
18 controls - a multicentre study. *J Oral Rehabil* 2015;42:127-135.  
19  
20  
21  
22 (19) Lu S, Baad-Hansen L, List T, Zhang Z, Svensson P. Somatosensory profiling of intra-oral  
23 capsaicin and menthol in healthy subjects. *Eur J Oral Sci* 2013;121:29-35.  
24  
25  
26  
27 (20) Maier C, Baron R, Tolle TR, Binder A, Birbaumer N, Birklein F et al. Quantitative sensory  
28 testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory  
29 abnormalities in 1236 patients with different neuropathic pain syndromes. *Pain*  
30 2010;150:439-450.  
31  
32  
33  
34  
35 (21) Pigg M, Baad-Hansen L, Svensson P, Drangsholt M, List T. Reliability of intraoral  
36 quantitative sensory testing (QST). *Pain* 2010;148:220-226.  
37  
38  
39  
40 (22) Baad-Hansen L, Pigg M, Ivanovic SE, Faris H, List T, Drangsholt M et al. Intraoral  
41 somatosensory abnormalities in patients with atypical odontalgia--a controlled multicenter  
42 quantitative sensory testing study. *Pain* 2013;154:1287-1294.  
43  
44  
45  
46  
47 (23) Baad-Hansen L, Pigg M, Ivanovic SE, Faris H, List T, Drangsholt M et al. Chairside  
48 intraoral qualitative somatosensory testing: reliability and comparison between patients  
49 with atypical odontalgia and healthy controls. *J Orofac Pain* 2013;27:165-170.  
50  
51  
52  
53 (24) Eberhard L. [Quantitative Sensory Testing in the facial area: a review]. *Z Evid Fortbild*  
54 *Qual Gesundheitswes* 2013;107:291-296.  
55  
56  
57  
58  
59  
60

- 1  
2  
3 (25) Lu S, Baad-Hansen L, Zhang Z, Svensson P. Reliability of a new technique for intraoral  
4 mapping of somatosensory sensitivity. *Somatosens Mot Res* 2013;30:30-36.  
5  
6  
7  
8 (26) Svensson P, Baad-Hansen L, Pigg M, List T, Eliav E, Ettlin D et al. Guidelines and  
9 recommendations for assessment of somatosensory function in oro-facial pain conditions--a  
10 taskforce report. *J Oral Rehabil* 2011;38:366-394.  
11  
12  
13  
14 (27) Poort LJ, van Neck JW, van der Wal KG. Sensory testing of inferior alveolar nerve injuries:  
15 a review of methods used in prospective studies. *J Oral Maxillofac Surg* 2009;67:292-300.  
16  
17  
18  
19 (28) Baad-Hansen L, Jensen TS, Svensson P. A human model of intraoral pain and heat  
20 hyperalgesia. *J Orofac Pain* 2003;17:333-340.  
21  
22  
23  
24 (29) Yekta SS, Smeets R, Stein JM, Ellrich J. Assessment of trigeminal nerve functions by  
25 quantitative sensory testing in patients and healthy volunteers. *J Oral Maxillofac Surg*  
26 2010;68:2437-2451.  
27  
28  
29  
30  
31 (30) Jaaskelainen SK, Teerijoki-Oksa T, Forssell H. Neurophysiologic and quantitative sensory  
32 testing in the diagnosis of trigeminal neuropathy and neuropathic pain. *Pain* 2005;117:349-  
33 357.  
34  
35  
36  
37 (31) List T, Leijon G, Svensson P. Somatosensory abnormalities in atypical odontalgia: A case-  
38 control study. *Pain* 2008;139:333-341.  
39  
40  
41  
42 (32) List T, Leijon G, Helkimo M, Oster A, Svensson P. Effect of local anesthesia on atypical  
43 odontalgia--a randomized controlled trial. *Pain* 2006;122:306-314.  
44  
45  
46  
47 (33) Agbaje JO, Mutsvari T, Lesaffre E, Declerck D. Measurement, analysis and interpretation  
48 of examiner reliability in caries experience surveys: some methodological thoughts. *Clin*  
49 *Oral Investig* 2012;16:117-127.  
50  
51  
52  
53 (34) McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med (Zagreb )*  
54 2012;22:276-282.  
55  
56  
57  
58  
59  
60

- 1  
2  
3 (35) Schmidt R, Schmelz M, Forster C, Ringkamp M, Torebjork E, Handwerker H. Novel  
4 classes of responsive and unresponsive C nociceptors in human skin. *J Neurosci*  
5 1995;15:333-341.  
6  
7  
8  
9 (36) Naganawa T, Baad-Hansen L, Ando T, Svensson P. Influence of topical application of  
10 capsaicin, menthol and local anesthetics on intraoral somatosensory sensitivity in healthy  
11 subjects: temporal and spatial aspects. *Exp Brain Res* 2015;233:1189-1199.  
12  
13  
14  
15 (37) Kilo S, Schmelz M, Koltzenburg M, Handwerker HO. Different patterns of hyperalgesia  
16 induced by experimental inflammation in human skin. *Brain* 1994;117:385-396.  
17  
18  
19  
20 (38) Koltzenburg M, Lundberg LE, Torebjork HE. Dynamic and static components of  
21 mechanical hyperalgesia in human hairy skin. *Pain* 1992;51:207-219.  
22  
23  
24  
25 (39) Baumann TK, Simone DA, Shain CN, LaMotte RH. Neurogenic hyperalgesia: the search  
26 for the primary cutaneous afferent fibers that contribute to capsaicin-induced pain and  
27 hyperalgesia. *J Neurophysiol* 1991;66:212-227.  
28  
29  
30  
31 (40) Shimada A, Castrillon E, Baad-Hansen L, Ghafouri B, Gerdle B, Ernberg M et al. Muscle  
32 pain sensitivity after glutamate injection is not modified by systemic administration of  
33 monosodium glutamate. *J Headache Pain* 2015;16:68. doi: 10.1186/s10194-015-0546-0.  
34 Epub@2015 Jul 22.:68-0546.  
35  
36  
37  
38 (41) Kothari SF, Baad-Hansen L, Andersen K, Svensson P. Neurosensory assessment in patients  
39 with total reconstruction of the temporomandibular joint. *Int J Oral Maxillofac Surg*  
40 2014;43:1096-1103.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1: Pooled data for healthy participants' response to QST and QualST modalities after application of Capsaicin and placebo. Each number represents the number of participants scoring normal, hyper- or hyposensitivity with QST and QualST

	Capsaicin						Placebo					
	TOUCH		COLD		PINPRICK		TOUCH		COLD		PINPRICK	
	<u>QST</u>	QualST	<u>QST</u>	QualST	<u>QST</u>	QualST	<u>QST</u>	QualST	<u>QST</u>	QualST	<u>QST</u>	QualST
Normal	12	6	12	6	16	5	17	18	18	16	18	17
Hypersensitivity	0	1	0	4	1	5	0	0	0	0	0	1
Hyposensitivity	6	11	6	8	1	8	1	0	0	2	0	0

Table 2: Percentage agreement between QST and QualST (Healthy participants)

	Capsaicin			Placebo		
	Touch (%)	Cold (%)	Pinprick (%)	Touch (%)	Cold (%)	Pinprick (%)
Absolute Agreement	11(61)	9 (50)	13 (72)	16 (89)	16 (89)	17 (94)
Disagreement	6 (33)	8 (44)	5 (28)	2 (11)	2 (11)	1 (6)
Absolute Disagreement	1 (6)	1 (6)	0 (0)	0 (0)	0 (0)	0 (0)



Table 3: The Sensitivity, Specificity of QualST given the status of QST (Healthy participants)

Parameter	Treatment	Hypersensitivity		Hyposensitivity	
		Sensitivity	Specificity	Sensitivity	Specificity
Touch	Capsaicin	-	0.94	0.83	0.50
	Placebo	-	1.00	-	1.00
Cold	Capsaicin	-	0.78	0.67	0.67
	Placebo	-	1.00	-	0.89
Pinprick	Capsaicin	1.00	0.76	1.00	0.59
	Placebo	-	0.94	-	0.94

The sensitivity is calculated as the probability of being classified as hyper- or hyposensitive with QualST when the subject was truly hyper- or hyposensitive with QST. When no subject was classified as hyper- or hyposensitive, no estimate (“-”) for the sensitivity was obtained.




Figure 1: Change in classification from quantitative sensory testing (QST) to qualitative sensory testing (QualST) in healthy participants. 0: normal; 1: hypersensitivity; 2: hyposensitivity.

127x90mm (300 x 300 DPI)




Figure 2 : Change in classification from quantitative sensory testing (QST) to qualitative sensory testing (QualST) in AO patients. 0: normal; 1: hypersensitivity; 2: hyposensitivity.

180x181mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3: Healthy participants-reported Numerical Rating Scale (NRS) pain scores  $\pm$  (SEM) after the topical application of capsaicin and placebo on the infra-orbital region. The results represent mean values (n = 18) obtained during the 5 min recording period.

110x77mm (300 x 300 DPI)




Figure 4 : Mean ( $\pm$ SD) of quantitative sensory testing (QST) parameters for tested condition before and after application in healthy participants.

88x44mm (300 x 300 DPI)




Figure 5: Mean ( $\pm$ SD) of quantitative sensory testing (QST) parameters for tested condition before and after application in healthy participants.

89x44mm (300 x 300 DPI)




Figure 6: Individual Z-score-based quantitative sensory testing (QST) profiles from the infraorbital region after the application of capsaicin and placebo in healthy participants and the averaged Z-scores (C) (n = 18). The grey area ( $-1.96 < z < 1.96$ ) is the normal range based on the healthy reference. CDT: cold detection threshold; WDT: warmth detection; TSL: thermal sensory limen; CPT: cold pain threshold; HPT: heat pain threshold; MDT: mechanical detection threshold; MPT: mechanical pain threshold; MPS: mechanical pain sensitivity; WUR: wind-up ratio; VDT: vibration detection threshold; PPT: pressure pain threshold.

100x56mm (300 x 300 DPI)